Abstract
Patients undergoing cancer chemotherapy are often challenging to physicians from a management standpoint due to an unfortunate combination of general poor health, immunosuppression, and multi-drug regimens. Several chemotherapeutic agents are associated with well-described mucocutaneous toxicities.
This chapter will address the commonly encountered adverse events associated with traditional chemotherapy medications such as chemotherapy-induced alopecia, mucositis, extravasation reactions, dyschromia, and acral erythema, among others. This will be followed by a discussion of the cutaneous toxicities associated with newer agents, namely, targeted therapies such as monoclonal antibodies and tyrosine kinase inhibitors. Finally, a brief discussion of radiation recall and enhancement is also included.
By addressing important considerations in the recognition, diagnosis, and management of the cutaneous effects of cancer treatment, additional morbidity and potential mortality can be avoided in this already at-risk patient population.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14:212–6.
Bernstein EF, Spielvogel RL, Topolsky DL. Recurrent neutrophilic eccrine hidradenitis. Br J Dermatol. 1992;127:529–33.
Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol. 1983;9:645–63.
Cox K, Stuart-Harris R, Abdini G, Grygiel J, Raghavan D. The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust. 1988;148:185–9.
DeSpain JD. Dermatologic toxicity of chemotherapy. Semin Oncol. 1992;19:501–7.
Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35:74–8.
Flynn TC, Harrist TJ, Murphy GF, Loss RW, Moschella SL. Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia. J Am Acad Dermatol. 1984;11:584–90.
Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am. 1986;70:187–209.
Johnson TM, Rapini RP, Duvic M. Inflammation of actinic keratoses from systemic chemotherapy. J Am Acad Dermatol. 1987;17:192–7.
Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci. 2001;321:327–35.
Laack E, Mende T, Knuffmann C, Hossfeld DK. Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine. Ann Oncol. 2001;12:1761–3.
Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982;49:1796–9.
Soto E, Fall-Dickson JM, Berger AM. Oral complications in cancer therapy. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott; 1993. p. 2385–94.
Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol. 1996;35:835–8.
Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491–500.
Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367–98; quiz 99–400.
Tosi A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf. 1994;10:310–7.
Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol. 2006;7:45–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Savas, J.A., Mahtani, R.L. (2014). Cutaneous Reactions to Chemotherapy. In: Hall, J. (eds) Skin Diseases in the Immunocompromised. Springer, London. https://doi.org/10.1007/978-1-4471-6479-1_8
Download citation
DOI: https://doi.org/10.1007/978-1-4471-6479-1_8
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-6478-4
Online ISBN: 978-1-4471-6479-1
eBook Packages: MedicineMedicine (R0)